Showing 161 - 180 results of 101,691 for search '(( 50 μ decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.37s Refine Results
  1. 161

    Shortening of mTL anticipates accumulation of DDR markers, decrease in cell proliferation and increase in apoptotis with age. by Madalena C. Carneiro (102302)

    Published 2016
    “…Other tissues' IF was quantified as overall % positive cells. Scale bar = 50 μm. N = 3–6 for tissue mTL quantifications per genotype per time point (x-axis in graphs of Fig 3E). …”
  2. 162
  3. 163
  4. 164
  5. 165

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  6. 166
  7. 167
  8. 168

    Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB. by David M. Mutch (37665)

    Published 2013
    “…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180

    Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

    Published 2022
    “…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”